Quick summary: Semaglutide is an FDA-approved GLP-1 receptor agonist shown in clinical trials to produce an average of roughly 15% body weight reduction when combined with lifestyle changes. It works by reducing appetite and slowing gastric emptying. It is not appropriate for everyone — a medical evaluation is required — and common side effects include nausea, vomiting, and gastrointestinal discomfort. OC Weight Loss & Med Spa in Mission Viejo offers medically supervised semaglutide treatment with ongoing provider support.
Medically reviewed by the clinical team at OC Weight Loss and Med Spa. Last updated: June 12, 2026.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of medication that mimics a naturally occurring gut hormone involved in appetite regulation and blood sugar control. It was originally approved by the FDA to manage type 2 diabetes (brand name Ozempic). A higher-dose formulation (brand name Wegovy) was later approved specifically for chronic weight management in adults with obesity or overweight with a weight-related health condition.
Semaglutide is administered as a once-weekly subcutaneous injection. Doses are increased gradually over several months to improve tolerability.
How Semaglutide Supports Weight Loss
Semaglutide acts on multiple pathways that govern hunger and energy balance:
- Appetite suppression: It activates GLP-1 receptors in the brain’s appetite-regulation centers, increasing feelings of fullness and reducing hunger between meals.
- Slowed gastric emptying: Food moves through the stomach more slowly, extending satiety after meals.
- Improved insulin sensitivity: The medication supports more effective glucose utilization, which is particularly relevant for patients with prediabetes or type 2 diabetes.
Together, these effects make it easier for many patients to sustain a calorie deficit without persistent hunger. Individual results vary.
What the Clinical Evidence Shows
The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program evaluated semaglutide 2.4 mg weekly in adults with obesity. In the pivotal STEP 1 trial, participants receiving semaglutide lost an average of approximately 15% of their initial body weight over 68 weeks, compared with about 2.4% in the placebo group. These were adults also following a reduced-calorie diet and increased physical activity.
Beyond weight, participants in the STEP trials saw improvements in waist circumference, blood pressure, and lipid levels — cardiovascular risk factors that commonly accompany obesity. These findings informed the FDA’s approval of Wegovy for chronic weight management.
Safety, Side Effects, and Who Should Not Use Semaglutide
Semaglutide is an effective tool for many patients, but it is not appropriate for everyone. The following information is a general overview — your provider will assess your complete medical history before recommending treatment.
Common side effects (most frequent during dose escalation):
- Nausea, vomiting, and diarrhea
- Constipation
- Stomach pain or indigestion
- Fatigue during early weeks of treatment
These effects are typically most pronounced during the first few weeks and tend to lessen as the body adjusts.
Serious risks to be aware of:
- Thyroid C-cell tumor risk: In animal studies, semaglutide caused thyroid C-cell tumors. It is unknown whether this applies to humans, but semaglutide carries an FDA boxed warning. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pancreatitis: Cases of acute pancreatitis have been reported. Patients with a history of pancreatitis should discuss this risk carefully with their provider.
- Gallbladder disease: Rapid weight loss of any kind can increase gallstone risk. Semaglutide has been associated with gallbladder-related events in clinical trials.
- Hypoglycemia: Risk increases when semaglutide is used alongside other diabetes medications, particularly sulfonylureas or insulin.
- Pregnancy: Semaglutide should be discontinued at least two months before a planned pregnancy. It is not recommended during pregnancy or breastfeeding.
Candidacy for semaglutide — including appropriate dosing and monitoring protocol — is determined at your consultation by a licensed medical provider.
Semaglutide at OC Weight Loss & Med Spa
At OC Weight Loss & Med Spa in Mission Viejo, CA, semaglutide is prescribed and supervised by our medical team. Lindsay Short, NP, is a board-certified Nurse Practitioner (UCLA chemistry BS, Columbia MSN) who leads patient consultations and ongoing weight management care. The clinic is physician-supervised by Dr. Nezar Dahdal, MD, board certified in Internal Medicine.
Our approach combines medication with individualized support — including monitoring, dosage adjustments, and lifestyle guidance. We review your health history, current medications, and goals to determine whether semaglutide is appropriate for your situation. For patients who are not candidates, other medically supervised weight loss options are available.
Frequently Asked Questions
How long does it take to see results with semaglutide?
Most patients begin to notice reduced appetite within the first few weeks. Measurable weight loss typically becomes apparent by weeks four to eight. Clinically significant weight reduction — as seen in the STEP trials — developed over 16 to 68 weeks of continuous treatment. Results depend on adherence, dietary habits, and individual metabolism. Individual results vary.
Do I have to stay on semaglutide indefinitely?
Obesity is a chronic condition, and GLP-1 medications appear to require ongoing use to maintain weight loss. Studies have shown that patients who discontinue semaglutide regain a significant portion of lost weight within a year. Your provider will discuss a long-term plan with you, including what continued treatment or a transition strategy might look like.
Is semaglutide the same as Ozempic or Wegovy?
Yes — semaglutide is the active ingredient in both Ozempic and Wegovy. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved specifically for weight management at 2.4 mg weekly. Compounded semaglutide is also available from certain pharmacies, though it is not FDA-approved in the same way as the brand-name products. Your provider will clarify which formulation is being prescribed and why.
Who is a good candidate for semaglutide?
FDA approval for weight management covers adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. However, BMI alone does not determine candidacy — contraindications, medical history, and current medications all factor into the decision. A comprehensive medical evaluation is the appropriate starting point.
What is the process at OC Weight Loss & Med Spa?
The process begins with a free consultation at our Mission Viejo office. Our provider reviews your health history, discusses your goals, and determines whether semaglutide is a medically appropriate option. If treatment begins, follow-up visits are scheduled to monitor progress, assess tolerance, and adjust dosing as needed. Financing options including Cherry, CareCredit, and Alle are available.
Schedule a Consultation
If you are considering semaglutide for weight management, the first step is a conversation with a qualified medical provider. OC Weight Loss & Med Spa offers free consultations at our Mission Viejo clinic, Monday through Friday 9 am to 5 pm and Saturday 9 am to 1 pm. You can also reach us at our contact page or call (949) 416-0950.
Book a free consultation
Book a Free Consultation